Department of Medical and Surgical Sciences and Advanced Technology "G.F. Ingrassia", University of Catania, Via Santa Sofia 86, Catania, Sicily, Italy.
U.O.C. General Surgery, ASP Siracusa, Contrada Colle Roggio, Lentini, Sicily, Italy.
Updates Surg. 2020 Sep;72(3):793-800. doi: 10.1007/s13304-020-00841-3. Epub 2020 Jul 6.
According to the American Joint Committee on Cancer, at least 12 lymph nodes are required to accurately stage locally advanced rectal cancer (LARC). Neoadjuvant chemoradiation therapy (NACRT) reduces the number of lymph nodes retrieved during surgery. In this study, we evaluated the effect of NACRT on lymph node retrieval and prognosis in patients with LARC. We performed an observational study of 142 patients with LARC. Although our analysis was retrospective, data were collected prospectively. Half the patients were treated with NACRT and total mesorectal excision (TME) and the other half underwent TME only. The number of lymph nodes retrieved and the number of metastatic lymph nodes were significantly reduced in the NACRT group (P > 0.001). In the univariate and multivariate analyses, only NACRT and patient age were significantly associated with reduced lymph node retrieval. The number of metastatic lymph nodes and the lymph node ratio (LNR) both had a significant effect on prognosis when the patient population was examined as a whole (P = 0.003 and P = 0.001, respectively). However, the LNR was the only significant, independent prognostic factor in both treatment groups (P = 0.007 for the NACRT group; P = 0.04 for the no-NACRT group). NACRT improves patient prognosis only when the number of metastatic lymph nodes is reduced. The number of metastatic lymph nodes and the LNR are important prognostic factors. Lymph node retrieval remains an indispensable tool for staging and prognostic assessment of patients with rectal carcinoma treated with NACRT.
根据美国癌症联合委员会的规定,至少需要 12 个淋巴结才能准确分期局部晚期直肠癌(LARC)。新辅助放化疗(NACRT)可减少手术过程中检出的淋巴结数量。在这项研究中,我们评估了 NACRT 对 LARC 患者淋巴结检出和预后的影响。我们对 142 例 LARC 患者进行了观察性研究。虽然我们的分析是回顾性的,但数据是前瞻性收集的。一半患者接受 NACRT 和全直肠系膜切除术(TME)治疗,另一半仅接受 TME 治疗。NACRT 组的淋巴结检出数和转移性淋巴结数显著减少(P>0.001)。在单变量和多变量分析中,只有 NACRT 和患者年龄与淋巴结检出减少显著相关。当整个患者群体进行检查时,转移性淋巴结数量和淋巴结比率(LNR)都对预后有显著影响(P=0.003 和 P=0.001)。然而,LNR 是两个治疗组中唯一具有显著独立预后意义的因素(NACRT 组 P=0.007;无 NACRT 组 P=0.04)。只有当转移性淋巴结数量减少时,NACRT 才能改善患者预后。转移性淋巴结数量和 LNR 是重要的预后因素。淋巴结检出仍然是接受 NACRT 治疗的直肠癌患者分期和预后评估不可或缺的工具。